Kang Stem Biotech Overview

  • Founded
  • 2010
  • Status
  • Public
  • Employees
  • 102
  • Stock Symbol
  • 217730
Stock Symbol
  • Share Price
  • $3.22
  • (As of Wednesday Closing)

Kang Stem Biotech General Information


Kangstem Biotech Co Ltd develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
Primary Office
  • 17th Floor, Shinan Building
  • 512 Teheran-ro, Gangnam-gu
  • Seoul
  • South Korea
+82 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kang Stem Biotech Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.22 $3.41 $3.22 - $7.60 $122M 37.9M 593K -$0.54

Kang Stem Biotech Financials Summary

In Thousands,
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 128,290 159,473 131,258 386,847
Revenue 7,545 7,739 5,149 8,339
EBITDA (13,230) (14,462) (20,200) (10,975)
Net Income (15,376) (15,644) (21,126) (12,418)
Total Assets 66,904 75,629 98,108 65,451
Total Debt 12,130 11,945 22,376 15,568
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kang Stem Biotech Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kang Stem Biotech‘s full profile, request access.

Request a free trial

Kang Stem Biotech Patents

Kang Stem Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210254005-A1 Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same Pending 23-Jan-2020 0000000000
US-20210222127-A1 Hla gene-deleted human induced pluripotent stem cell-derived mesenchymal stem cells and preparation method thereof Pending 30-May-2018 0000000000
EP-3805370-A1 Hla gene-deleted, human induced pluripotent stem cell-derived mesenchymal stem cell and preparation method therefor Pending 30-May-2018 0000000000
US-20190365820-A1 Complex for promoting cartilage differentiation comprising cartilage cell-free crush and stem cell and use thereof Pending 04-Jul-2016 0000000000
EP-3479834-A4 Complex comprising cartilage cell-free lysate and stem cell for promoting cartilage differentiation and use thereof Pending 04-Jul-2016 A61K35/32 0

Kang Stem Biotech Executive Team (3)

Name Title Board Seat Contact Info
Na Jong-cheon Chief Executive Officer
Kang Kyung-sun Founder
Chang-kyu Choi Senior Vice President
To view Kang Stem Biotech’s complete executive team members history, request access »

Kang Stem Biotech Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kang Stem Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kang Stem Biotech‘s full profile, request access.

Request a free trial